Q1 FY 20 Performance Update

We believe that the changes in market dynamics have created exciting opportunities. We have what it takes to win in the generics industry Strong R&D, API, complex generics, biologics, specialty (1200+ scientists, 350+ PhDs) 00 Low cost operations Broad portfolio - Differentiated, complex, back integrated Six spaces set up for growth (US, China, Russia, India, API, Hospitals) Commitment to operational excellence, safety, and compliance Stable ownership and strong management team with dedicated employees .00 Strong balance Quality sheet Strong brand identity Customers & stakeholders orientation (Customers, Regulators, Vendors, Partners) PROPRIETARY

View entire presentation